Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just keeping it real been daytrading 20 years hype is fun but once it dries up move on…. Plenty of opportunities
Tahoe
your comment on the potential market is spot on. Just how many DOGS need diarrhea medicine can there be?? What will it sell for,? Profit margin
all come to mind as questions.
Why I said my biggest concern is with whats a justifiable target price even if they get the PH3 results approved by the fda..
That said tho, when it comes to momentum on PR, there is no way to judge how long a 'run' will last, how high the share price goes, till its over..
Good luck..
Disclaimer: still observing the 'skirmish' taking place for direction. Who knows, maybe it will consolidate at the price range of 30-32 cents.. That would be nice to
see.. Would show nice support...
But let's do .48 first. Then pull back.....
Looking on the daily, i still think it can revisit ~.26 before going higher, a healthy pullback. If no news the following days, it could do this, imo.
The issue is that there are already a bunch of old school meds that are very effective and also very cheep.
So…. If marketing just towards chemotherapy patients, pretty small market in animals.
From my Vet friend
still looking for direction.. Volume appears to be tapering off in comparison to the prior 2 days of heavy volume as it rallied up.
Now appears that 'both' sides are wondering who 'blinks' first..
Breaks .33 it’s off to the races again 10% up days I’m cool with slow and steady not rocketship and dump
Told everyone over at MOMO group maybe they jumping in now
Shot just go green Positive already! the surge will come this afternoon
Hoping it goes over .40 this week. That would be sweet. Jags should be able to push over a dollar without a split.
Looks like the heard jumped into other 20%+ bangers today… AGBA MULN SOUN.. oh well they will be back in… GMZP if you wanna play that kinda game. JAGX is my highest position right now with 50,777 shares yes I love gambling lol
Next leg up coming :)
JAGX
Even looking at a elementary level 5 and 1 month line chart all points to going North!
Guessing the whole bit on rumor sell on news??? So dumb
Talked to one of my customers who is a Colorectal surgeon he said thumbs up looks legit so I’m buying more….
sounds very exciting - do you have a link to read this great NEWS?
Hey everyone happy monday! It is a warzone over on stocktwits lol, I'm doing my best to educate people to not listen to the paid shorts. The news today is amazing honestly, how cool is it that Crofelemer has multiple indications and JAGX is the only company with full rights to all licensing??! It made my day!
for a few minutes now, JAGX has been turning green - wow, look how strong - and apparently wants to take off upwards, so I jumped back in 🔥🔥🔥🔥🔥🔥🔥 https://www.nasdaq.com/market-activity/stocks/jagx/real-time 🚀🚀🚀🚀
imho
$JAGX boom apparently it's just starting up again https://www.nasdaq.com/market-activity/stocks/jagx/real-time
Bit of profit taking on the open this morn??
Lot of volume, running in place kind of guides to this conclusion (??)
And its early, so see how it goes today. Still a good % above its MA line.. Question is, does it run in place while the MA line catches up or does it go looking for it?? TBD'd..
Note: The MA is now at 22 cents/sh with a steep upslope to it, so it can catch up in a hurry.. but its 50% below the current share price.. but it can move in a hurry... so ....
Disclosure: I sold out Friday at 30.2 cents... happy with what I was able to get. Pondered it pulling back.. if it does consolidate?? Might get another round Good luck
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
https://jaguarhealth.gcs-web.com/news-releases/news-release-details/crofelemer-jaguar-healths-prescription-drug-conditionally
10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE)
WONDER IF WE HEAR ANYTHING BACK ON THIS TODAY???
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
Jaguar Health, Inc.
Mon, May 6, 2024
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has established a new Investigational New Animal Drug (INAD) file with the Center for Veterinary Medicine (CVM) of the U.S. Food and Drug Administration (FDA) for the company's novel plant-based prescription drug crofelemer to treat general, non-infectious diarrhea in dogs.
Crofelemer delayed-release tablets, under the name Canalevia®-CA1, received conditional approval in December 2021 from the FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
"We're very pleased to have established this new INAD file," said Michael Guy, DVM, MS, PhD, Jaguar's Vice President of Preclinical and Nonclinical Studies. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet need for a product to treat general, non-infectious diarrhea in dogs as well. We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to evaluating the possibility of expanding the indication of crofelemer to include treatment of all types of non-infectious diarrhea in dogs. The next step in our development process is to request a pre-submission conference with the CVM to discuss our proposed protocol for the clinical field study for this new indication."
Jaguar previously issued results from a multicenter, randomized, double-blind, controlled proof-of-concept study that assessed the efficacy of crofelemer administered orally in alleviating clinical signs associated with secretory diarrhea in dogs. The study results showed that crofelemer was superior to placebo.
Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea. According to the American Veterinary Medical Association, there were an estimated 83 million to 88 million dogs in the United States in 2020, and 45% of U.S. households owned a dog in 2020. Devastating dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs.
Important Safety Information About Canalevia-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
https://finance.yahoo.com/news/crofelemer-jaguar-health-prescription-drug-123000791.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAAKJJfX_vPfZTzE_Hfko3f-AE6cU-Azs2AH1wLCrYSoE3uAIjnXNZwk5SkxgM1j93Qn5jZP59Ff_GM7A4nlhLykve6b1vhJ9z2qcttGb87M8Z6SulNJZhqydV6N4Vb-NXyXfHBEmZYoaH0mY_UQmwV7PUmBvJmjOvadD38vV3zHy4
$JAGX
''We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs''
BENZINGA: Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea
Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment
REUTERS
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
JAGX seems to be consolidating in a northward trajectory as shown in the monthly chart as compared to 4/30-5/2.. However consider dips in low 20's to high teens a possibility yet a terrific buying opportunity if all else stays the same. IMO
New PR : Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
.40c next resistance level
Good morning Jaguarundis JAGX
Monday could be a nice green day.
Not sure what you are 'concerned' about, but I would be asking about the POTENTIAL REVENUE stream..
And ponder, how many 'units' of product will the market DEMAND/NEED.. and how much could they sell it for...
et al.. Thats the part that I am looking for clarification on as it will help guide the 'target price'..
Right now, its running on expectations, momentum.. Which is more than ok as it gets off the 'floor'.
Course, at this point, ANY additional sales would be a positive..
And Sam Bankman-Fried knew a lot about bitcoin too just saying….
Jagx has a board of certified doctors
Common sense would tell me if anyone in the house is a doctor or knows of a doctor if they could get back to all of us who are non-medical and see if this is really legit or what their thoughts are thanks!!!
$JAGX another huge week coming up .
Just hope we all just not drinking the kool-Aid… no way been daytrading for 20 years ALLL SIGNS POINT UP!!!!!
Check this video I saw on TikTok https://www.tiktok.com/t/ZTLCL6C7W/
Gotcha… PR comes out what we all waiting for and they have until Aug this year to get to $1.00 or RS coming once again
The point was they jump in on moving stocks with volume. JAGX already had the volume and moving.
They added to the volume buying and then the selling and shorting. And repeating
Over the last year JAGX was on alerts a few times.
Probably all of Tim Sykes and his little minions pulling out for the week to get their beer money
Pull up any 1 or 2 year chart look at volume and Green Day’s recently HUGE MOMO play!
Apparently we need AI programs not Tim lol
Followers
|
151
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6877
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody crudeoil24 SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |